News Release
Investors
![](/media/5meaatds/1.png)
![](/media/z5qfflsv/2.png)
![](/media/sl1h3yuj/3.png)
![](/media/haof1cy1/4.png)
![](/media/jb4jmyyw/5.png)
![](/media/ctck221v/6.png)
Partners
![](/media/decktw1v/2.png)
![](/media/hyyhh5fc/3.png)
![](/media/firfve3j/4.png)
![](/media/zuupehxm/5.png)
![](/media/nuniyctv/6.png)
![](/media/uk3n5ptp/logo1.png)
![](/media/5xxngzom/logo2.png)
![](/media/y1tnshba/logo3.png)
![](/media/1hanwle2/scriptr-01.png)
![](/media/tplctku0/university-of-washington01.png)
Our Pipeline
We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in patients with rare genetic diseases.
Our Products
Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).
![](/media/wkpahxsz/product.png)
Corporate Culture & Career
To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China
Contact Us
![](/media/1gxgrasw/map_background.png)
Beijing
Beijing
Room1501, 15/F(16), No. 10, Futong East Street, Chaoyang District, Beijing.
Tel: 010 6478 0016
Fax: 010 6478 0019
E-mail: info@canbridgepharma.com
Adverse Events Reporting: PV@canbridgepharma.com
Shanghai
Shanghai
Suite 708, Huawen International Mansion, No.999, West Zhongshan Road, Changning District, Shanghai
Tel: 021 52956319
Fax: 021 52665300
E-mail: info@canbridgepharma.com
Adverse Events Reporting: PV@canbridgepharma.com
Hong Kong
Hong Kong
Rm B01, 20/F, CITIC Tower, 1 Tim Mei Avenue, Admiralty, Hong Kong
Adverse Events Reporting: PV@canbridgepharma.com
Taiwan
Taiwan
Room209, 2F, No. 141, Sec. 1, Keelung Rd., Xinyi Dist., Taipei, Taiwan
Adverse Events Reporting: PV@canbridgepharma.com
Burlington
Burlington
4 Burlington Woods Drive, Burlington, MA 01803, USA